Hasil Pencarian - Laura Stanbery

  • Menampilkan 1 - 19 hasil dari 19
Perbaiki Hasil
  1. 1
    Ovarian Cancer Immunotherapy and Personalized Medicine

    Ovarian Cancer Immunotherapy and Personalized Medicine oleh Susan Morand, Monika Devanaboyina, Hannah Staats, Laura Stanbery, John Nemunaitis

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report

    HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report oleh Dylan Fortman, Rochell Issa, Laura Stanbery, Mary Albrethsen, John Nemunaitis, Timothy Kasunic

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    FDA efficiency for approval process of COVID-19 therapeutics

    FDA efficiency for approval process of COVID-19 therapeutics oleh Christine Cassidy, Danielle Dever, Laura Stanbery, Gerald Edelman, Lance Dworkin, John Nemunaitis

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Systemic benefit of radiation therapy via abscopal effect

    Systemic benefit of radiation therapy via abscopal effect oleh Daniel J. Craig, Stephanie Ambrose, Laura Stanbery, Adam Walter, Adam Walter, John Nemunaitis

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer

    Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer oleh John Nemunaitis, Laura Stanbery, Adam Walter, Adam Walter, Rodney Rocconi, Philip Stephens, Philip Stephens

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

    Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer oleh Minal Barve, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, Laura Stanbery, John Nemunaitis

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Adenomatous polyposis coli in cancer and therapeutic implications

    Adenomatous polyposis coli in cancer and therapeutic implications oleh Olivia Noe, Louis Filipiak, Rachel Royfman, Austin Campbell, Leslie Lin, Danae Hamouda, Laura Stanbery, John Nemunaitis

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer

    Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer oleh Morgan Bailey, Susan Morand, Rachel Royfman, Leslie Lin, Aditi Singh, Laura Stanbery, Adam Walter, Danae Hamouda, John Nemunaitis

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

    Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6 oleh Vedin Barve, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal Barve, John Nemunaitis

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Subclonal landscape of cancer drives resistance to immune therapy

    Subclonal landscape of cancer drives resistance to immune therapy oleh Daniel J. Craig, Morgan M. Bailey, Olivia B. Noe, Kada K. Williams, Laura Stanbery, Danae M. Hamouda, John J. Nemunaitis

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Homologous recombination proficiency in ovarian and breast cancer patients

    Homologous recombination proficiency in ovarian and breast cancer patients oleh Justin Fortune Creeden, Nisha S. Nanavaty, Katelyn R. Einloth, Cassidy E. Gillman, Laura Stanbery, Danae M. Hamouda, Lance Dworkin, John Nemunaitis

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Resident Memory T Cells and Their Effect on Cancer

    Resident Memory T Cells and Their Effect on Cancer oleh Daniel J. Craig, Justin F. Creeden, Katelyn R. Einloth, Cassidy E. Gillman, Laura Stanbery, Danae Hamouda, Gerald Edelman, Lance Dworkin, John J. Nemunaitis

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

    Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer oleh Rodney P. Rocconi, Laura Stanbery, Luciana Madeira da Silva, Robert A. Barrington, Phylicia Aaron, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Adam Walter, John Nemunaitis

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]

    Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (202... oleh Jonathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance

    Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance oleh Johnathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    3D engineered scaffold for large-scale Vigil immunotherapy production

    3D engineered scaffold for large-scale Vigil immunotherapy production oleh Fabienne Kerneis, Ernest Bognar, Laura Stanbery, Seongjun Moon, Do Hoon Kim, Yuxuan Deng, Elliot Hughes, Tae-Hwa Chun, Darron Tharp, Heidi Zupanc, Chris Jay, Adam Walter, John Nemunaitis, Joerg Lahann

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells

    A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells oleh Seongjun Moon, Dylan B. Neale, Do Hoon Kim, Malini Mukherji, Elliot Hughes, Yuxuan Deng, Fabienne Kerneis, Xiuquan Luo, Darron Tharp, Ernest Bognar, Laura Stanbery, John Nemunaitis, Tae-Hwa Chun, Joerg Lahann

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

    ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer oleh Rodney P. Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J. Monk, Thomas J. Herzog, Robert L. Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John Nemunaitis

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

    Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer oleh Rodney P. Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J. Monk, Thomas J. Herzog, Robert L. Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John Nemunaitis

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: